A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

NCT06058728 | Withdrawn DMC

• 1 other identifier: P20-400
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Uterine Fibroids (UF) are benign smooth muscle neoplasms of the uterus that affect women of reproductive age. UFs are one of the leading causes of hospitalizations for gynecological disorders and often lead to hysterectomy. In this study, women with heavy menstrual bleeding (HMB) due to UF who are being treated with Oriahnn will be followed to establish the incidence rate, time to onset, extent, pattern, and resolution of meaningful hair loss, as well as any racial differences. Oriahnn is an approved drug for the management of HMB associated with UF. All study participants will receive Oriahnn as prescribed by their study doctor in accordance with approved local label. Study Participants will be followed for up 24 months (part 1). Approximately 1600 participants aged 18-50 years will be enrolled at 1 site in the United States. Participants will receive oral Oriahnn as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for 24 months. There is expected to be no additional burden for participants in this trial. Participants will complete questionnaires on a quarterly basis.

Conditions

Uterine Fibroids (UF)

Keywords

Uterine Fibroids (UF); Heavy Menstrual Bleeding (HMB); Oriahnn; Elagolix; Estradiol; Norethindrone Acetate

Outcome Measures

Primary Outcomes (7)

• Percentage of Participants with Meaningful Hair Loss

  Meaningful hair loss is defined as patient-reported changes in thickness, fullness, or pattern of hair that results in less hair than normal or hair shedding that is increased from normal in the Hair Questionnaire.

  Up to Month 24

• Time to Onset of Hair Loss

  Time from initiation of Oriahnn until patient-reported meaningful hair loss will be assessed.

  Up to Month 42

• Changes in Patterns of Hair Loss

  Based on example description and images of alopecia subtypes, changes in patterns of hair loss are classified as primary pattern of hair loss.

  Up to Month 42

• Number of Participants with Improvement in Hair Loss

  Defined as a report that since the participant has reported hair loss, her hair loss has improved.

  Up to Month 42

• Number of Participants with Resolution in Hair Loss

  Resolution in hair loss is defined as a report that since the patient has reported hair loss, her hair has returned to normal.

  Up to Month 42

• Time to Resolution in Hair Loss

  Time from onset of meaningful hair loss until reported resolution.

  Up to Month 42

• Number of Participants who Discontinued Oriahnn at Reported Hair Loss

  Discontinuations of Oriahnn at or after reported hair loss will be calculated.

  Up to Month 42

Study Arms (2)

Part 1 - Oriahnn Exposure Cohort

Participants prescribed Oriahnn for management of heavy menstrual bleeding (HMB) due to uterine fibroids (UF).

Part 2 - Nested Hair Loss Cohort

Participants prescribed Oriahnn for management of HMB due to UF, with meaningful hair loss.

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Women 18 to 50 years old with heavy menstrual bleeding (HMB) due to uterine fibroids (UF).

You may qualify if:

• Part 1:
• International Classification of Disease-10 (ICD-10) diagnosis codes for both uterine fibroids (UF) (D25.X) and heavy menstrual bleeding (HMB), defined as menorrhagia (N92.0, N92.4) or menometrorrhagia (N92.1) in the electronic health record (EHR) system.
• Plans to initiate or has initiated Oriahnn treatment within 14 days of study enrollment.
• Able to provide photographs of their scalp within 14 days of Oriahnn initiation, based on instruction provided.
• Part 2:
• \- Changes in thickness, fullness or pattern of hair that results in less hair than normal, or hair shedding that is increased from normal in the Hair Questionnaire.

You may not qualify if:

• Current or history of hair thinning, hair loss, or alopecia (defined as physician-diagnosed or patient-reported hair loss).
• Have a contraindication to receive Oriahnn per Prescribing Information.
• Any of the following occurrences within 180 days prior to Oriahnn prescription.
• Prescription for Oriahnn, another gonadotropin releasing hormone (GnRH) antagonist \[including Myfembree (relugolix, estradiol/norethindrone acetate\]) or GnRH agonist.
• Pregnancy/Childbirth.
• New diagnosis of thyroid disease.
• New diagnosis of inflammation or infection of the scalp (e.g., psoriasis, tinea capitis).
• Have taken medications or undergone therapies that may cause alopecia, hair loss, or both. This includes but is not limited to chemotherapy, checkpoint inhibitors, epidermal growth factor antagonists, or radiation anywhere on the body.
• Initiation or changes in medications or doses for the management of thyroid diseases
• Any other medical condition or surgery requiring hospitalization (other than UF)

Sponsors & Collaborators

• AbbVie: lead

Study Sites (1)

Dorsata /ID# 252675

Arlington, Virginia, 22201-5330, United States

Location

Related Links

• Related Info

MeSH Terms

Conditions

Leiomyoma; Menorrhagia

Condition Hierarchy (Ancestors)

Neoplasms, Muscle Tissue; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Uterine Hemorrhage; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Menstruation Disturbances

Study Officials

• ABBVIE INC.

  AbbVie

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2023
• First Posted: September 28, 2023
• Study Start: December 20, 2023
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: September 17, 2025

Record last verified: 2025-09

Locations

US (1)